Immune-Onc Therapeutics is a clinical-stage startup operating in the healthcare sector, specifically in the field of cancer immunotherapy. The company is pioneering a new class of treatments known as myeloid checkpoint inhibitors, which are believed to be the next big thing in cancer immunotherapy. These inhibitors work by targeting immune suppressive pathways, potentially transforming the current treatment approaches for both blood cancers and solid tumors.

Immune-Onc's business model revolves around research and development, with a focus on creating a portfolio of these novel inhibitors. The company collaborates with scientists, academic institutions, and non-profit cancer organizations to discover and develop new immunomodulatory approaches to cancer treatment. Their clients are primarily patients suffering from various types of cancer who could benefit from immunotherapy.

The company operates in the biopharmaceutical market, a sector characterized by high research and development costs, long product development cycles, and a complex regulatory environment. Immune-Onc generates revenue through the development and eventual commercialization of its innovative cancer treatments. The company's efforts are supported by investors with significant industry experience, who are committed to making the company's vision a reality for patients.

Keywords: Cancer Immunotherapy, Myeloid Checkpoint Inhibitors, Clinical-Stage Startup, Research and Development, Collaboration, Biopharmaceutical Market, Blood Cancers, Solid Tumors, Investors, Commercialization.